全文获取类型
收费全文 | 2218篇 |
免费 | 117篇 |
国内免费 | 20篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 54篇 |
妇产科学 | 84篇 |
基础医学 | 344篇 |
口腔科学 | 33篇 |
临床医学 | 168篇 |
内科学 | 386篇 |
皮肤病学 | 30篇 |
神经病学 | 302篇 |
特种医学 | 45篇 |
外科学 | 278篇 |
综合类 | 8篇 |
预防医学 | 236篇 |
眼科学 | 22篇 |
药学 | 203篇 |
肿瘤学 | 154篇 |
出版年
2023年 | 6篇 |
2022年 | 13篇 |
2021年 | 44篇 |
2020年 | 16篇 |
2019年 | 27篇 |
2018年 | 45篇 |
2017年 | 39篇 |
2016年 | 52篇 |
2015年 | 46篇 |
2014年 | 73篇 |
2013年 | 84篇 |
2012年 | 154篇 |
2011年 | 152篇 |
2010年 | 84篇 |
2009年 | 75篇 |
2008年 | 134篇 |
2007年 | 158篇 |
2006年 | 143篇 |
2005年 | 164篇 |
2004年 | 155篇 |
2003年 | 138篇 |
2002年 | 134篇 |
2001年 | 26篇 |
2000年 | 30篇 |
1999年 | 32篇 |
1998年 | 31篇 |
1997年 | 23篇 |
1996年 | 12篇 |
1995年 | 6篇 |
1993年 | 7篇 |
1992年 | 14篇 |
1991年 | 20篇 |
1990年 | 11篇 |
1989年 | 6篇 |
1988年 | 15篇 |
1987年 | 15篇 |
1986年 | 13篇 |
1985年 | 17篇 |
1984年 | 7篇 |
1983年 | 7篇 |
1979年 | 15篇 |
1978年 | 12篇 |
1976年 | 6篇 |
1975年 | 16篇 |
1974年 | 8篇 |
1973年 | 8篇 |
1972年 | 6篇 |
1969年 | 7篇 |
1968年 | 6篇 |
1960年 | 5篇 |
排序方式: 共有2355条查询结果,搜索用时 15 毫秒
91.
We present the case of a 38-year-old man in whom extensive bilateral melorheostosis was associated with elevated serum alkaline phosphatase, swelling of the right foot and progressive deformity of the left hand, left leg and right foot. Radiography, computed tomography and bone scintigraphy were performed. Following treatment with bisphosphonate (30 mg/day of pamidronate for 6 days) infusion, the pain and swelling of his right foot showed improvement and his elevated serum alkaline phosphatase decreased. 相似文献
92.
93.
Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo. 总被引:2,自引:0,他引:2
Rita C Dardes Ruth M O'Regan Csaba Gajdos Simon P Robinson David Bentrem Alex De Los Reyes V Craig Jordan 《Clinical cancer research》2002,8(6):1995-2001
PURPOSE: Cross-resistance is an important issue for the evaluation of new antiestrogens to treat advanced breast cancer patients who have failed tamoxifen therapy. In addition, postmenopausal patients treated with long-term adjuvant tamoxifen show a 3-4-fold increase in the risk of developing endometrial cancer. Consequently, a new second line agent should be more antiestrogenic and less estrogen-like on the uterus, and be effective at controlling the growth of breast cancer after exposure to tamoxifen. The purpose was to evaluate the effects of the new tamoxifen analogue GW5638 on breast and endometrial cancer growth. EXPERIMENTAL DESIGN: Athymic mice were transplanted with an endometrial tumor model (ECC-1 E2) that is responsive to estrogen and has never been exposed to antiestrogen. In addition, we used three breast tumor models: a tamoxifen-na?ve tumor (T47D-E2) and two tamoxifen-stimulated tumors (MT2 TAM and MCF-7 TAM LT). The antiestrogen GW5638 (1.5 mg daily), tamoxifen (0.5 mg or 1.5 mg daily), and raloxifene (1.5 mg daily) were given p.o. The pure antiestrogen ICI182,780 (5 mg once a week) was given s.c. Western blots from MCF-7 TAM breast tumors were performed to demonstrate the regulation of estrogen receptor alpha expression by different ligands. RESULTS: Estradiol and GW5638 down-regulated the receptor compared with control. ICI182,780 completely degraded the receptor but tamoxifen had no effect. GW5638 did not promote tumor growth, and was effective in blocking the effects of postmenopausal estradiol on the growth of tamoxifen-na?ve breast and endometrial tumors. However, raloxifene did not completely block the effects of postmenopausal estradiol on the growth of tamoxifen-na?ve endometrial tumor after 14 weeks. GW5638 and ICI182,780 but not raloxifene were also effective in blocking the tamoxifen-stimulated breast tumor growth in athymic mice. CONCLUSIONS: GW5638 is more effective than raloxifene in blocking the effect of estrogen on tamoxifen-na?ve endometrial cancer. More importantly, GW5638, like the pure antiestrogen ICI182,780, is able to block the growth of breast cancer stimulated by tamoxifen differently from raloxifene. GW5638 down-regulates estrogen receptor but does not completely destroy the receptor. Therefore, based on our findings, GW5638 could be developed as a second line agent for advanced breast cancer patients and an important first line agent to evaluate as an adjuvant treatment or chemopreventive. 相似文献
94.
95.
96.
L Fésüs L Muszbek B Csaba 《International archives of allergy and applied immunology》1975,49(4):540-547
In active anaphylactic shock of rats pretreated with Bordetella pertussis vaccine, both plasma thrombin clotting time and the amount of antigenically active fibrinogen degradation products in the serum were increased. The formation of clottable fibrinogen fragments was shown by SDS polyacrylamide gel electrophoresis of thrombin-induced clots. When plasma of rats pretreated with 125I rat fibrinogen and then subjected to anaphylaxis was submitted to SDS polyacrylamide gel electrophoresis, fibrinogen-split products were also detected. Fibrinogen degradation results from the proteolytic effect of an activated fibrinolytic enzyme. 相似文献
97.
98.
Csaba M. Banki 《Psychopharmacology》1978,56(2):195-198
Cerebrospinal fluid 5-hydroxyindoleacetic acid level, and total blood serotonin content was measured in groups of manic and schizophrenic patients before and after 2, 4, 6, 10, 20, and 30 days of clozapine treatment. CSF 5-HIAA values were elevated after 2 and 4 days and returned to baseline levels after 6 days or more. Blood serotonin content, in contrast, increased gradually and remained high even after 30 days. Neither CSF 5-HIAA nor blood 5-HT correlated with age, drug dose, or clinical effectiveness, but some relationship between these and the sedative component of the clozapine action was observed. 相似文献
99.
100.